Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula

Completed · Not applicable · Has a placebo group

Conditions studied: Improve Endothelial Function and Decrease Vascular Stenosis

In brief

Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has been the site for recruitment of patients requiring new vascular access for the last 10 years.

Key facts

Study ID

NCT02414204

Run by

University of Alabama at Birmingham

People needed

4

Starts

2015-04-01

Expected to finish

2018-06-30

Last updated by the study team

2019-08-12

Who can join

Age: 19 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥19 years of age male or female
• Chronic Kidney Disease Stage IV or V patients or End Stage Renal Disease Patient requiring arteriovenous fistula surgery

You may not qualify if…

• Patient currently on nitrate therapy or any nitric oxide donor in any form
• Patient currently on protease inhibitor or non-nucleoside reverse transcriptase inhibitor
• Patient with resting systolic blood pressure <90 mm Hg and diastolic blood pressure < 50 mm Hg.
• Patient life expectancy < nine months.
• Patient unable or unwilling to meet study requirements.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.